Tormax

Quick links to important sections

Tormax

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tormax

Tormax is the trade name for a potent prescription-only synthetic medication whose active ingredient is Torasemide (also identified as Torsemide). It serves as a foundational treatment for conditions involving fluid retention and high blood pressure, strictly addressing the core issue of fluid balance in the body.

Property Description
Active ingredient Torasemide (Torsemide)
Form Tablet (Oral formulation), Intravenous (IV) Solution
Pharmacological class Loop Diuretic (High-Ceiling Diuretic)
Common use Management of excess fluid and high blood pressure
Origin Synthetic (Pyridine-sulfonylurea derivative)

What Type of Medicine is Tormax (Torasemide)?

Tormax is officially classified as a Loop Diuretic, a type of medicine frequently termed a High-Ceiling Diuretic due to its significant efficacy. The active substance, Torasemide, is a single-ingredient product synthesized chemically as a pyridine-sulfonylurea derivative, which places its action specifically within the kidney's water and salt processing structures. Torasemide is used to help the kidneys remove water and salt from the body. This categorization is key to understanding its powerful effects, as it differs from weaker or alternative classes of diuretics in its speed and magnitude of action.


Composition and Available Drug Forms

The core composition of Tormax is the active pharmaceutical ingredient Torasemide, which is provided to patients in two standard forms for systemic delivery. It is most commonly found as an oral formulation in a tablet suitable for ingestion, allowing for convenient long-term management. The drug is also prepared as an Intravenous (IV) solution, which is reserved for direct administration into the bloodstream in clinical settings, enabling a rapid onset of its desired effects. The availability of both oral and intravenous routes allows for continuous management across different phases of patient care.


What is the General Purpose of Torasemide?

The general purpose of Torasemide is to vigorously manage the body's fluid and salt levels, thereby reducing excess volume and lowering vascular resistance. This outcome is achieved because Torasemide initiates increased diuresis (the forceful excretion of water) and increased natriuresis (the strong elimination of sodium salts) by blocking key transporters in the kidney. Torasemide is characterized by its potency and longer half-life compared to other diuretics. This suggests the drug is effective in maintaining a more consistent therapeutic effect over time, often allowing for convenient once-daily dosing. This fundamental pharmacological action provides the core benefit for relieving conditions characterized by unwanted fluid buildup, known as edema, and is centrally used to aid in the long-term control of systemic arterial hypertension (high blood pressure) via its combined fluid-reducing and subtle vasodilatory effect.

Regulatory References

  1. MedlinePlus

What side effects are possible with Tormax?

The safety profile for Tormax is dependent on its active pharmaceutical ingredient, which, based on regulatory labeling, may be Topiramate (an antiepileptic) or Torsemide (a loop diuretic).

Adverse Reactions (Common)

Active Ingredient Common Reactions (from Clinical Trials)
Topiramate Paresthesia (tingling), somnolence (drowsiness), weight decrease, anorexia, fatigue, dizziness, and psychomotor slowing.
Torsemide Excessive urination, dizziness, headache, dehydration, decreased blood pressure, and metabolic/electrolyte abnormalities (e.g., hypokalemia).

Serious and Clinically Significant Adverse Reactions

Topiramate is associated with risks including acute myopia and secondary angle closure glaucoma (a potentially permanent visual impairment), metabolic acidosis, oligohidrosis (decreased sweating) leading to hyperthermia, suicidal behavior and ideation, and kidney stones. Use during pregnancy carries a risk of oral clefts in the infant.

Torsemide is associated with risks of symptomatic hypotension, worsening renal function (including acute renal failure), significant electrolyte and metabolic abnormalities, and ototoxicity (hearing loss or tinnitus, usually reversible). Rare but severe skin reactions such as Stevens-Johnson syndrome have been reported.

Population and Use Restrictions

  • Topiramate: Contraindicated for migraine prevention in pregnancy; requires gradual withdrawal; caution with concomitant use of other carbonic anhydrase inhibitors or a ketogenic diet. Doses above 200 mg/day may decrease the effectiveness of estrogen-containing oral contraceptives.
  • Torsemide: Contraindicated in patients with anuria, hepatic coma, or known hypersensitivity to the drug. Requires periodic monitoring of fluid status, renal function, and serum electrolytes. Elderly patients may be more susceptible to dehydration and hypotension. Dose titration should be closely monitored.

Overdose and Emergency Response

Overdose of Tormax (Torasemide) is officially documented to result primarily from the consequences of marked diuresis and subsequent excessive fluid and electrolyte loss. The reported clinical manifestations of an overdose include signs of dehydration, confusion, somnolence, and hypotension (low blood pressure). Severe physiological abnormalities such as hyponatremia (low sodium) and hypokalemia (low potassium) are key documented outcomes.

Regulatory documents specify that the potential severe or life-threatening outcomes of Tormax overdose may include circulatory collapse and the risk of thrombosis or embolism due to hemoconcentration. This risk is noted to be present especially in elderly patients.

When an overdose is suspected, official guidance mandates that individuals seek emergency medical attention immediately. If the person has collapsed, has trouble breathing, or cannot be awakened, emergency services must be contacted. Management is symptomatic and supportive, focusing on the simultaneous replacement of lost fluid and electrolytes, as regulatory labeling confirms that no specific antidote is known.

Therapeutic Uses of Tormax

Tormax (Torasemide) is applied across domains where additional symptomatic support is needed, typically when patients experience symptoms related to systemic imbalance and fluid retention, and may assist with maintaining functional stability. This medication is relevant for managing conditions that cause edema, including heart, kidney, or liver disease, as well as high blood pressure.


Therapeutic Focus and Relief

Tormax is commonly used to help with conditions presenting with systemic or localized discomfort, such as generalized fluid accumulation (edema) in the legs and feet. It is considered relevant in conditions where functional stability becomes affected, including chronic diseases like heart failure and severe kidney or liver disease. The core benefit contributes to easing the overall symptom load by supporting the management of excess fluid volume. This may assist with reducing physical swelling and the related discomfort.

Relief of Cardio-Pulmonary Congestion

Tormax is considered relevant for easing symptoms linked to organ-specific functional stress, such as cardio-pulmonary congestion, where fluid accumulation causes distress in the chest and lungs. This application is commonly used to help with symptoms that interfere with daily functioning, such as shortness of breath, often seen in symptomatic heart failure. By managing this internal fluid, Tormax supports the patient during difficult episodes by easing distress and may help improve day-to-day comfort during periods of heightened symptoms.

Control of Systemic Arterial Hypertension

Tormax may be part of symptomatic management in the treatment of Systemic Arterial Hypertension (high blood pressure). In this domain, the medication plays a role in managing symptoms related to systemic imbalance. This therapeutic strategy provides supportive relief when symptoms interfere with routine activities, and may be part of symptomatic management for high blood pressure.

Quick Fact: Relief for Peripheral Edema Tormax is relevant for easing symptom clusters that may become intense or disruptive, such as the noticeable swelling of the ankles and legs.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Tormax (Torasemide) is officially established for use in adults for conditions requiring fluid management, including older adults, though caution and potential dose adjustment may be necessary in the elderly. The drug’s regulatory eligibility profile is strictly defined by absolute exclusions and conditions requiring special caution.


Absolute Exclusions (Contraindications)

Use of Tormax is contraindicated (must not be used) in patients with known hypersensitivity to Torasemide or sulfonylureas, and in individuals who are anuric (unable to pass urine). It is also contraindicated for patients currently experiencing hepatic coma or pre-coma.

Restricted or Conditional Use

The medicine requires special caution in patients with certain pre-existing conditions:

  • Hepatic Impairment: Patients with hepatic disease, such as cirrhosis and ascites, must be monitored carefully, often necessitating concurrent use of a potassium-sparing diuretic.
  • Fluid Imbalances: Individuals with severe hypovolaemia, hypotension, or existing severe electrolyte depletion (e.g., severe low potassium or sodium) are generally restricted from use until these states are corrected.
  • Pediatric Patients: Safety and effectiveness have not been established in children and adolescents.
  • Pregnancy and Lactation: Use is not recommended during pregnancy or breastfeeding due to a lack of established human data and potential risks documented in animal studies.

What should I know about interactions with other medicines?

Tormax Interactions with other medicines and products

Torasemide, the active ingredient in Tormax, has officially documented interaction patterns based on its metabolic pathway and pharmacodynamic effects, as classified in regulatory documents.

Metabolic and Exposure Alterations

Co-administration with CYP2C9 Inhibitors is documented to decrease torasemide clearance, resulting in increased plasma concentrations (exposure). Conversely, CYP2C9 Inducers (e.g., Rifampin) increase clearance, decreasing Tormax exposure. Tormax may also affect the efficacy of sensitive CYP2C9 Substrates (e.g., Warfarin, Phenytoin) due to its metabolic activity.

Pharmacodynamic and Toxicity Risks

Pharmacodynamic interactions include a potentiated risk of hypotension when combined with other antihypertensive agents. The risk of ototoxicity is increased with co-administered Aminoglycosides or Cisplatin. Concomitant use with Corticosteroids or ACTH increases the risk of hypokalemia (low potassium). Nonsteroidal Anti-inflammatory Drugs (NSAIDs) can reduce the antihypertensive and diuretic effects of Tormax.

Timing and Absorption Rules

A timing restriction applies to Cholestyramine, which decreases Tormax absorption. Tormax must be administered at least one hour before or four to six hours after Cholestyramine. Population-specific notes indicate that in patients with Decompensated Congestive Heart Failure, total clearance is reduced by approximately 50%, increasing plasma exposure.

Mechanism of Action

Targeted Blockade of Renal Salt Transport

Torasemide's action is defined by a dual mechanism resulting in modulation of extracellular fluid volume and vascular tone, rooted in targeted molecular intervention within the kidney and peripheral tissues.

The primary mechanism involves the direct inhibition of the Sodium-Potassium-2-Chloride ( Na^+/ K^+/2 Cl^-) Cotransporter (NKCC2), the specialized ion channel located in the Loop of Henle. By directly blocking this transporter, the molecule prevents the kidney from reabsorbing a large fraction of filtered sodium, chloride, and water. This molecular interference initiates an osmotic cascade, resulting in the high-volume excretion of salt (natriuresis) and water (diuresis), altering the body's extracellular fluid volume.

Extra-Renal Vascular Tone Modulation

Beyond its primary renal mechanism, Torasemide engages in secondary extra-renal vascular modulation. The mechanism involves dampening the downstream effects of vasoconstrictive hormones, such as Angiotensin II, on the smooth muscle lining of blood vessels. This activity results in the reduction of peripheral vascular resistance, a physiological change that complements the volume mechanism by modulating the resistance experienced by the circulatory system.

Dosage and Administration Information

The administration of Tormax (torasemide) is governed by official prescribing information, which details the approved routes, frequency, and population-specific dosage limitations. The medication is officially available in two formats for systemic delivery: an oral tablet for long-term use and an intravenous (IV) solution reserved for clinical settings when a rapid effect is required.

Torasemide is administered once daily for all approved indications. The oral tablet should preferably be taken in the morning and may be consumed with or without food.

Official Dosing and Titration

Dosage is initiated at a low level and adjusted upward (titrated) based on the patient's clinical response, but must not exceed regulatory-defined maximums. The initial once-daily doses are: 5 mg for hypertension and 10 mg or 20 mg for most edema cases. For managing hypertension, the maximum dose is 10 mg once daily, with the full blood pressure effect taking approximately four to six weeks to establish.

Indication (Starting Dose) Maximum Daily Dose Special Constraint
Edema (10 mg or 20 mg) 200 mg None
Hypertension (5 mg) 10 mg None
Edema in Hepatic Cirrhosis (5 mg or 10 mg) 40 mg Must be co-administered with a potassium-sparing diuretic

Special Procedural Notes

The medicine's use for edema in patients with hepatic cirrhosis mandates a lower maximum daily dose of 40 mg and concomitant use with a potassium-sparing diuretic. For older adults, no specific initial dosage adjustments are required solely based on age. If a dose is missed, patients are instructed to skip the missed dose if it is almost time for the next scheduled dose and not to double doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tormax (Torasemide)

Evidence for Fluid Management in Chronic Heart Failure (CHF)

Research into Torasemide's use in chronic heart failure (CHF) has involved several types of investigations, including Randomized Controlled Trials (RCTs) and large observational studies. Researchers used these trials to monitor several outcomes, including changes in body weight, adjustments in the NYHA functional class (a measure of daily functioning), and the frequency of heart failure-related re-hospitalizations.

Findings from these studies describe patterns related to measured changes in fluid and sodium excretion during the study period. Studies also show measured changes in symptom scores and functional class in the observed populations. Some research has examined Torasemide in trials against other similar medicines (like Furosemide) to explore long-term patient events, such as re-hospitalization rates and mortality. Some findings described mixed patterns, while other large randomized trials reported that no difference was observed in these outcomes between the two study arms.

What remains uncertain is the long-term data for mortality and major cardiovascular events across all patients, as the available evidence is mixed or largely derived from observational data. The extent to which the results apply to wider patient populations may be limited in some smaller trials, as the evidence describes group patterns and not personal outcomes.


Evidence for Fluid Management in Kidney and Liver Conditions

Torasemide was studied for its use in managing fluid retention (edema) associated with advanced chronic kidney disease and abdominal fluid accumulation (ascites) related to hepatic cirrhosis.

In the context of kidney disease, research focused on Controlled Clinical Trials to see how the drug performed in patients with reduced kidney function. Findings indicate that Torasemide was associated with fluid and sodium removal in some studies in this population. The research highlights that the dose required to achieve diuresis may increase as kidney function declines. For hepatic disease (cirrhosis), studies explored the drug's use, often in combination with other medicines, and monitored weight loss due to fluid mobilization. While research describes patterns of fluid and weight reduction, the follow-up durations were limited in many of these specialized studies.


What is Still Uncertain About Torasemide Research

Despite the body of research from clinical trials and observational data, several areas of uncertainty remain in the Torasemide evidence landscape.

Long-term effects are not fully established for major clinical outcomes in all approved indications, particularly when the drug is used outside of chronic heart failure management. Comparative evidence is lacking in some areas, especially concerning whether Torasemide provides a measurable difference compared to other diuretics across all measured outcomes in all patients. Findings were mixed in some head-to-head trials regarding outcomes like all-cause mortality and overall re-hospitalization rates. The overall evidence quality varies across studies, with some key findings relying on open-label (non-blinded) or retrospective designs, which carry inherent limitations.

Key Studies & References

  1. Torasemide in Edema Associated with Chronic Kidney Disease (Review/Summary of Clinical Data)
  2. Torasemide in Edema Associated with Hepatic Impairment (Review/Summary of Clinical Data)
  3. Torasemid Zentiva Public Assessment Report (Generic MA for Hypertension, CHF, Edema)

Frequently Asked Questions (FAQ)

Common questions about Tormax (FAQ)


Q: Is Tormax the same type of medicine as [similar generic drug]?

A: Torasemide, the active ingredient in Tormax, belongs to the loop diuretic class of medicines. Official regulatory documents indicate that drugs in this class share a similar primary action in the kidney to help the body eliminate excess fluid and salt. It is therefore chemically similar to other medicines in the same category.


Q: Why is Tormax sometimes preferred over older medicines for the same condition?

A: Clinical overviews suggest that Torasemide has a higher bioavailability (meaning more of the drug is absorbed by the body) and a longer duration of action compared to some older loop diuretics. These characteristics may be considered by prescribers, potentially supporting a once-daily dosing schedule.


Q: How quickly should a patient expect Tormax to start making a noticeable difference?

A: According to pharmacokinetic data, Torasemide is typically rapidly absorbed after being taken orally, with the drug reaching its highest concentration in the blood in about one hour. The rapid absorption means the pharmacological action of fluid reduction begins shortly after the drug is administered.


Q: Are there any common but minor side effects that often go away after a few weeks of taking Tormax?

A: Official patient information indicates that some common side effects, such as dizziness, headache, or increased urination, may be mild at first. These effects may sometimes lessen or resolve on their own as the body adjusts to the medication, but this must be monitored by a healthcare provider.


Q: What is the general safety classification for Tormax according to regulators?

A: Torasemide is classified as a prescription-only (℞-only) medication by health regulators. Regarding pregnancy, it is generally listed as a Pregnancy Category B drug in the US or not recommended in the EU, which signifies that use during pregnancy requires assessment by a healthcare professional.


Q: What happens if Tormax does not appear to be working?

A: When a medicine does not appear to provide the expected effect, the healthcare provider may re-evaluate the patient's condition and consider the possibility of dose titration up to the maximum level specified in regulatory guidelines.


Q: What types of food or drinks are listed in official documents as potentially interacting with Tormax?

A: While Torasemide can be taken with or without food, official patient instructions often recommend that individuals follow a low-salt or low-sodium diet as part of the overall treatment plan for fluid retention or high blood pressure. Any specific dietary restrictions should be discussed and followed as directed by the patient’s healthcare provider.


Q: Is there a generic version of Tormax available, or is it only available as a brand name?

A: Yes, the active ingredient Torasemide is widely available globally as a generic medication. It is manufactured and marketed under various different brand names depending on the country of sale.


Q: How does the research evidence for Tormax compare to the evidence for other treatments?

A: Some clinical studies have indicated that Torasemide was associated with differences in rehospitalization rates for heart failure when compared to other diuretics. However, overall research evidence indicates no statistically significant difference in outcomes like all-cause mortality across all comparative trials.


Q: Were the clinical trials for Tormax conducted on a large and diverse patient population?

A: Official documents often note that findings from clinical trials are based on observed group patterns within the study cohort. This means the overall results describe the population studied, and the extent to which they apply to wider, more diverse patient populations may be limited in some smaller trials.


Q: Is Tormax known to cause any long-term effects after discontinuing its use?

A: Stopping Torasemide abruptly should only be done under the instruction of a healthcare professional. Uncontrolled cessation may lead to an uncontrolled spike in blood pressure or a rapid return of fluid retention, which is associated with an elevated risk of serious cardiovascular events.


Q: What happens in the body when Tormax reaches its peak concentration?

A: Pharmacokinetic data indicates that when Torasemide reaches its peak concentration in the bloodstream, it is actively working in the kidneys. At this point, the drug is exerting the maximum effect of diuresis (water excretion) and natriuresis (sodium excretion). The physiological activity of blocking the NKCC2 transporter is at its maximum at this time.


Q: Is Tormax safe for people with a history of heart conditions?

A: Torasemide is often used to treat heart failure. However, official information highlights that caution is necessary because the medicine can lower potassium levels, which in turn may increase the risk of an abnormal heart rhythm, especially in individuals with existing heart issues or those taking certain concurrent medicines like digoxin.


Q: What precautions related to sun exposure are mentioned for Tormax?

A: Regulatory summaries indicate that Torasemide may cause a photosensitivity reaction, which makes the skin more vulnerable or sensitive to damage from sunlight. Any concerns regarding sun exposure and precautions should be discussed with a healthcare provider.


Q: Are there any specific lifestyle changes that are recommended in official documents while on Tormax?

A: Official patient information often advises following any prescribed low-salt (low-sodium) diet while taking the medication. A healthcare professional may provide specific instructions on the intake of potassium-rich foods or supplements.


Q: Does taking Tormax affect a person's ability to drive or operate machinery?

A: Torasemide may cause side effects such as dizziness, lightheadedness, or fainting, which could impair motor function. The potential for dizziness or fainting means individuals should exercise caution before driving or operating hazardous machinery until they are aware of how the medication affects them.


Q: Is Tormax classified as addictive or habit-forming?

A: Torasemide is not classified as a controlled substance under the US Controlled Substances Act (CSA) schedule. It is generally not considered to have addictive or habit-forming potential.


Q: What does 'contraindication' mean in the context of Tormax's use?

A: In medical terms, a contraindication is an official regulatory statement that the medicine should not be used in a specific situation, such as having certain diseases or conditions (like anuria). This exclusion is mandated because using the drug under those circumstances could be dangerous or life-threatening.


Q: Does Tormax have a 'Black Box Warning' in the US, and what does that indicate?

A: The US FDA label for Torasemide does not contain a Boxed Warning (the highest level of warning). However, the label does detail significant risks, such as symptomatic hypotension and electrolyte imbalances, in the main Warnings and Precautions section.


Q: Is there a risk of withdrawal symptoms if Tormax is stopped suddenly?

A: Official information states that stopping Torasemide suddenly without medical guidance is not recommended. Stopping abruptly may cause a rapid increase in blood pressure, which is associated with an elevated risk of serious cardiovascular events.


Q: Does Tormax require any routine monitoring or blood tests while being used?

A: Yes, regulatory guidelines require routine monitoring. Doctors will periodically check a patient's serum electrolytes (such as potassium and sodium) and renal function (kidney function). This monitoring is required because the drug alters the body's fluid and salt balance.


Q: Is it possible to have an allergic reaction to Tormax, and what are the signs to watch for?

A: Yes, allergic reactions are possible, and hypersensitivity is listed as a contraindication. Signs of a severe allergic reaction (anaphylaxis) can include hives, trouble breathing or swallowing, or swelling of the throat or tongue. The onset of these symptoms indicates a need for immediate medical evaluation.


Q: What is the typical timeframe for a doctor to assess the success of Tormax treatment?

A: The official product information notes that the full blood pressure-lowering effect of Torasemide may take approximately four to six weeks to fully establish. This timeframe serves as a common period for healthcare professionals to assess the drug's initial success and determine if any dose adjustments are needed.


Q: Does the efficacy of Tormax change if a patient is taking certain supplements or herbal products?

A: Regulatory documents state that patients should ensure their healthcare provider is aware of all prescription, over-the-counter, vitamin, nutritional, and herbal products they are taking. This is because some supplements may influence the drug's effectiveness or the necessary monitoring requirements.


Q: What were the key findings of the phase 3 clinical trials for Tormax?

A: Clinical trial summaries indicate that the medicine was associated with measurable changes in fluid and sodium excretion in the studied groups. These changes led to documented improvements in fluid-related symptoms and functional class in certain populations with conditions like chronic heart failure.


Q: Is Tormax approved for use in countries outside of the United States?

A: Yes, the active ingredient Torasemide is approved and available under various brand names in multiple countries around the world. Regulatory authorities in Europe and other regions also have official approval documents for its use.


Q: What is the official source of information for reporting side effects experienced with Tormax?

A: The official source for reporting side effects is the national drug regulatory authority. In the United States, patients can report adverse events to the FDA's MedWatch program, while in other regions, there is a similar national system for voluntary reporting.


Q: Does Tormax have any restrictions related to certain surgical procedures or dental work?

A: Discussions with a healthcare provider prior to a surgical procedure are important, as the use of diuretics may need to be adjusted on the day of surgery due to their effect on blood pressure. Regulatory overviews suggest caution is necessary due to the potential for hypotension.


Q: Are weight changes a possible side effect of taking Tormax?

A: The primary goal of Torasemide is to remove excess fluid, which commonly results in weight loss related to the fluid reduction. However, a rapid, unintended weight loss may be a sign of a serious complication, such as severe dehydration, and warrants medical evaluation.


Q: What kind of patient education materials are officially available for Tormax?

A: Official patient education materials are available from drug manufacturers and regulators, such as the Patient Information Leaflet (PIL) in the EU or Medication Guides in the US. These documents provide detailed, factual information about its use, risks, and storage.


Q: Is it normal for Tormax to cause a change in sleep patterns?

A: Clinical and postmarketing data includes reports of insomnia (difficulty sleeping) and nervousness as potential side effects of Torasemide. Any unusual or sustained changes in sleep patterns should be discussed with a healthcare provider.


Q: How does the body eliminate Tormax after it has been taken?

A: According to pharmacokinetic studies, Torasemide is cleared from the body mainly by hepatic metabolism, which means it is processed by the liver. The majority of its clearance is performed by the liver, with the rest of the drug being excreted via the urine.


Q: What is the expected long-term safety profile of Tormax based on available research?

A: Official summaries indicate that while long-term effects for some major clinical outcomes are still being studied, Torasemide is associated with a safety profile similar to other medicines in its class. Continued periodic monitoring of renal function and serum electrolytes is a mandatory part of its long-term use.

How should Tormax be stored and disposed of?

How to Store and Dispose of Tormax (Torasemide) Tablets

The storage and disposal of Tormax (Torasemide) must adhere strictly to the conditions mandated in government-approved labeling.

Official Storage Conditions

The medicine must be kept at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F). The tablets must be protected from moisture and excessive heat and should not be frozen. It is required to store the medication in its original container and ensure the container remains tightly closed.

Safety and Disposal Mandates

The regulatory labeling requires that the product be kept out of the sight and reach of children.

When disposing of expired or unused Tormax, it must not be flushed down the toilet or poured into a drain unless specifically instructed by local authorities. All disposal must be performed according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tormax found in:

A-Z Index: